Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

View/ Open
Date
2017-05-11ICR Author
Author
Barr, PM
Brown, JR
Hillmen, P
O'Brien, S
Barrientos, JC
Reddy, NM
Coutre, S
Mulligan, SP
Jaeger, U
Furman, RR
Cymbalista, F
Montillo, M
Dearden, C
Robak, T
Moreno, C
Pagel, JM
Burger, JA
Suzuki, S
Sukbuntherng, J
Cole, G
James, DF
Byrd, JC
Type
Journal Article
Metadata
Show full item recordAbstract
Key Points Higher ibrutinib DI is associated with improved PFS, independent of del17p or TP53 mutation. Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.
Collections
Language
eng
License start date
2017-05-11
Citation
Blood, 2017, 129 (19), pp. 2612 - 2615
Publisher
American Society of Hematology